课题基金 / 基金详情

项目摘要

项目成果

JAMES Gegan MILLER的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Fracture risk associated with osteoporosis represents a concern that is likely to become ever more serious as the nation's population ages. The FDA has approved 7 drugs designed to slow or reverse osteoporosis. The gold standard for monitoring pharmacological treatment is Dual Energy X-ray Absorptiometry (DEXA), which provides a measure of bone mineral density (BMD). In principle, bone sonometry is capable of providing additional information regarding bone quality because it is sensitive not only to bone mineral density but also to microstructure and orientation which influence fracture risk. In spite of its promise, however, sonometry has not yet been shown to provide such additional bone quality information, in part because of the specific limitations to be addressed in the proposed research. Phase cancellation at the receiving transducer has a negative impact on bone sonography. Transmission of ultrasound through bone is results in the generation of multiple modes of propagation including fast and slow waves, mode convertion, and multiple scattering - effects that can mask the underlying material properties of bone that determine fracture risk. At present, sonometry is limited to sites permitting through transmission such as the cancaneus, whereas sites at highest risk of fracture such as the hip would be accessible only to backscattered ultrasound. We have therefore identified three specific aims: 1) Identify, segregate, and overcome limitations of current transmission-based calcaneus sonometry arising from phase cancellation at the receiving transducer, 2) implement Bayes inversion of the ultrasonic signals to estimate the underlying bone material properties from received transmission sonometry signals complicated by the presence of multiple modes, and 3) validate, expand, and refine methods for estimating fracture risk in high risk sites such as the hip based on backscattered ultrasound. The long-term goal of the proposed research is to enhance and expand bone sonometry to facilitate its role in monitoring bone quality and the potential regression of osteoporosis with the aid of pharmacological interventions. PUBLIC HEALTH RELEVANCE: Osteoporotic fractures reduce quality of life and carry enormous health care costs. Sonometry could improve bone quality assessment because, unlike DEXA, it is sensitive to bone microstructure and orientation. The proposed research addresses fundamental improvements to existing sonometry techniques, and explores new techniques applicable to the hip and spine that are at relatively high risk of fracture but currently cannot be monitored.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
BAYESIAN ENHANCEMENT OF ECHOCARDIOGRAPHIC STRAIN ASSESSMENT
  • 批准号:
    8403974
  • 项目类别:
  • 资助金额:
    $18.09万
  • 财政年份:
    2012
  • 负责人:
    JAMES Gegan MILLER
  • 依托单位:
BAYESIAN ENHANCEMENT OF ECHOCARDIOGRAPHIC STRAIN ASSESSMENT
  • 批准号:
    8235639
  • 项目类别:
  • 资助金额:
    $22.8万
  • 财政年份:
    2012
  • 负责人:
    JAMES Gegan MILLER
  • 依托单位:
Enhancing Bone Quality Assessment Using Quantitative Ultrasound
  • 批准号:
    8097436
  • 项目类别:
  • 资助金额:
    $30.86万
  • 财政年份:
    2009
  • 负责人:
    JAMES Gegan MILLER
  • 依托单位:
Enhancing Bone Quality Assessment Using Quantitative Ultrasound
  • 批准号:
    7871451
  • 项目类别:
  • 资助金额:
    $31.33万
  • 财政年份:
    2009
  • 负责人:
    JAMES Gegan MILLER
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: